ClinConnect ClinConnect Logo
Search / Trial NCT05080283

Acceptance and Performance of CP1110 Sound Processor With Experienced Adult Cochlear Implant Recipients.

Launched by COCHLEAR · Oct 13, 2021

Trial Information

Current as of June 10, 2025

Completed

Keywords

ClinConnect Summary

The clinical study aims to investigate acceptance, actual-use usability and speech performance with a new behind-the-ear sound processor (model number: CP1110) system, compared with the commercially available Nucleus 7 Sound Processor (model: CP1000) system, with particular focus on the acceptance of and satisfaction with a noise reduction feature in the Automatic Scene Classifier 'SCAN 2'. This study will build on the evidence collected in previous Nucleus 7 Sound Processor take home studies and will also aim to confirm the in-booth performance of CP1110 and Nucleus 7 Sound Processors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Aged 18 years or older.
  • 2. Post lingually deafened.
  • 3. Implanted with the CI600 Series (CI612, CI632, CI622, CI624), CI500 Series (CI512, CI532, CI522) or Freedom Series (CI24RE(CA), CI24RE(ST), CI422).
  • 4. At least 6 months experience with a cochlear implant.
  • 5. At least 3 months experience with a Nucleus 7 (CP1000) Sound Processor
  • 6. Able to score 30% or more at +15 SNR with CI alone on a sentence in babble test
  • 7. Willingness to participate in and to comply with all requirements of the protocol.
  • 8. Fluent speaker in English as determined by the investigator
  • 9. Willing and able to provide written informed consent
  • Exclusion Criteria:
  • 1. Additional disabilities that would prevent participation in evaluations.
  • 2. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedures.
  • 3. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  • 4. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
  • 5. Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
  • 6. Currently participating, or participated in another interventional clinical study/trial in the past 30 days or if less than 30 days, the prior investigation was Cochlear sponsored and determined by the investigator to not impact clinical findings of this investigation.

About Cochlear

Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.

Locations

Sydney, New South Wales, Australia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials